Zacks: Brokerages Expect Ra Pharmaceuticals (RARX) to Announce -$0.53 Earnings Per Share

Equities research analysts predict that Ra Pharmaceuticals (NASDAQ:RARX) will announce earnings of ($0.53) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings. Ra Pharmaceuticals reported earnings per share of ($0.56) in the same quarter last year, which suggests a positive year-over-year growth rate of 5.4%. The business is expected to announce its next quarterly earnings report on Wednesday, August 8th.

On average, analysts expect that Ra Pharmaceuticals will report full year earnings of ($2.26) per share for the current year, with EPS estimates ranging from ($2.30) to ($2.22). For the next financial year, analysts anticipate that the firm will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.24) to ($1.95). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ra Pharmaceuticals.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.05).

RARX has been the topic of several recent research reports. Credit Suisse Group reduced their price target on shares of Ra Pharmaceuticals from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, February 13th. SunTrust Banks reaffirmed a “buy” rating on shares of Ra Pharmaceuticals in a report on Thursday, March 15th. BMO Capital Markets reduced their price target on shares of Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a report on Thursday, March 15th. Finally, ValuEngine downgraded shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $19.50.

Several institutional investors and hedge funds have recently made changes to their positions in RARX. Paloma Partners Management Co acquired a new position in Ra Pharmaceuticals during the fourth quarter worth approximately $154,000. Two Sigma Investments LP acquired a new stake in shares of Ra Pharmaceuticals in the fourth quarter worth $164,000. Cubist Systematic Strategies LLC increased its position in shares of Ra Pharmaceuticals by 817.8% in the first quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock worth $106,000 after acquiring an additional 17,820 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Ra Pharmaceuticals by 166.2% in the third quarter. Wells Fargo & Company MN now owns 23,842 shares of the company’s stock worth $348,000 after acquiring an additional 14,885 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Ra Pharmaceuticals by 76.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 28,937 shares of the company’s stock worth $246,000 after acquiring an additional 12,516 shares in the last quarter. 47.89% of the stock is currently owned by institutional investors and hedge funds.

Shares of Ra Pharmaceuticals traded down $0.05, hitting $6.22, on Thursday, according to MarketBeat.com. The company’s stock had a trading volume of 80,425 shares, compared to its average volume of 110,187. Ra Pharmaceuticals has a 12-month low of $4.78 and a 12-month high of $25.63. The company has a market capitalization of $200.83 million, a PE ratio of -2.58 and a beta of 2.05.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply